"The strong start to the year of our Japanese business was particularly encouraging, with sales growth driven by Advair and Relenza. The opportunity for GSK, in the Japanese market is significant with a substantial schedule of new product launches to come, including newly received approvals for Allermist and Tykerb."
"Sales of antiviral treatment Relenza were £222 million in the quarter, reflecting significant orders for pandemic stockpiling from the UK and Japanese Governments."
BTA Price at posting:
78.0¢ Sentiment: Buy Disclosure: Held
